Detail akcie Vericel online

Business Summary: Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Vericel Corp revenues increased 11% to $115.8M. Net loss increased 38% to $11.8M. Revenues reflect MACI segment increase from $40.2M to $99.8M, Epicel segment increase of 27% to $13.6M, NexoBrid segment increase from $436K to $2.5M, United States segment increase from $52.7M to $115.8M. Higher net loss reflects United States segment loss increase from $6M to $14.8M.